Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest valproic acid Stories

2008-11-06 09:00:44

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the three-month and nine-month periods ended September 30, 2008. Noven reported net income of $5.2 million, or $0.21 diluted earnings per share, for the quarter ended September 30, 2008. Results for the third quarter of 2008 included the recognition of $5.0 million in operating income due to the reversal of an accrued liability for a Pexeva(R) contingent sales milestone payment and an aggregate $6.0 million...

2008-10-21 09:00:12

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat. The data will be presented at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer...

2008-10-14 09:00:44

SiDMAP, a provider of flux-based, metabolic profiling services, has expanded its SiDTox services to enable rapid and specific detection of drug-induced organ toxicity. Based on research performed by SiDMAP in collaboration with the Center for Metabolomics at the FDA National Center for Toxicological Research, SiDTox now also includes a cost-effective and non-invasive test which promises to better enable pharmaceutical researchers to rapidly detect drug-induced toxicity prior to organ...

b5d2f6635c6ba71ec9c3826b9d336c8d1
2008-10-13 13:15:00

Researchers said on Sunday they found a shortcut to transforming ordinary skin cells into powerful stem cells by "sprinkling" a chemical onto the cells. The team at the Harvard Stem Cell Institute in Massachusetts added the chemical to use just two genes to transform ordinary human skin cells into more powerful induced pluripotent stem cells or iPS cells. "This study demonstrates there's a possibility that instead of using genes and viruses to reprogram cells, one can use chemicals," said Dr....

2008-08-06 09:01:04

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the second quarter and first half of 2008. Noven reported net income of $4.5 million or $0.18 diluted earnings per share for the quarter ended June 30, 2008, including a charge of $1.7 million (discussed below) relating to a previously disclosed voluntary product recall initiated during the quarter. Excluding this charge and related tax effects, Noven would have reported net income of $5.6 million or $0.23 diluted...

2008-07-31 09:01:25

By John Dorschner, The Miami Herald Jul. 31--Noven Pharmaceuticals, the drug maker with headquarters in South Miami-Dade, said the U.S. Food and Drug Administration has approved Stavzor, a delayed-release capsule used to treat patients with bipolar disorder, certain types of seizures and migraine headaches. Stavzor will be the first pipeline drug to reach the marketplace that was developed by Noven Therapeutics, a subsidiary specializing in medications that don't use patches, said Noven...

2008-07-30 09:00:23

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Stavzor(TM) (valproic acid delayed release capsules) in 125 mg, 250 mg and 500 mg strengths. Stavzor is approved for the treatment of manic episodes associated with bipolar disorder, as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures, and for...

2008-07-30 09:00:23

Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, today announced that the US Food & Drug Administration (FDA) has granted final approval for the Company's New Drug Application (NDA) for Valproic Acid Delayed Release soft gelatin capsules in the 125 mg, 250 mg, and 500 mg strengths. This drug is approved for use in the treatment of manic episodes associated with bipolar disorder, as monotherapy and adjunctive...

2008-06-18 15:00:44

Researchers in Victoria, Australia have developed a new genetic test to help predict the response of epilepsy sufferers to commonly used drug treatments. The non-invasive blood-based test has been developed by doctors from the Royal Melbourne Hospital, Melbourne University and the Murdoch Children's Research Institute. Victoria Innovation Minister Gavin Jennings said the work involving Victorian researchers is featured in the Innovation Corridor here at the BIO International Conference....

2006-08-07 16:57:39

By Anthony J. Brown, MD NEW YORK (Reuters Health) - Roughly 20 percent of epileptic women who take the antiseizure drug valproate during pregnancy will have a fetus with a serious adverse outcome, almost twice the rate associated with the next most problematic antiepileptic drug, new research shows. Several years ago, the American Academy of Neurology and other groups issued guidelines for treating epileptic women during pregnancy. Since antiepileptic drugs, in general, have been...